Extracellular Vesicles as Innovative Tools for Assessing Adverse Effects of Immunosuppressant Drugs.
Extracellular vesicles
adverse effects
biomarkers
immunosuppressants
therapeutic efficacy
therapy personalization
Journal
Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
06
2021
revised:
19
10
2021
accepted:
22
10
2021
pubmed:
10
12
2021
medline:
27
5
2022
entrez:
9
12
2021
Statut:
ppublish
Résumé
Extracellular vesicles (EVs) are a heterogeneous family of small vesicles released by donor cells and absorbed by recipient cells, which represent important mediators with fundamental roles in both physiological and pathological conditions. EVs are present in a large variety of biological fluids and have a great diagnostic and prognostic value. They have gained the interest of the scientific community due to their extreme versatility. In fact, they allow us to hypothesize new therapeutic strategies since, in addition to being cell signal mediators, they play an important role as biomarkers, drug vehicles, and potential new therapeutic agents. They are also involved in immunoregulation, have the ability to transmit resistance to a drug from one cell to a more sensitive one, and can act as drug delivery systems. The main reciprocal interactions between EVs and immunosuppressive drugs will be presented. The known interactions between EVs and immunosuppressive drugs, in particular cyclosporin, glucocorticoids, rapamycin, methotrexate, cyclophosphamide, eculizumab, infliximab, certolizumab, etanercept, glatiramer acetate, and fingolimod are presented. This review provides relevant information on the links between EVs and immunosuppressive drugs with a focus on EVs' role as tools to assess the effects of immunosuppressants, suggesting innovative properties and new possible therapeutic uses.
Sections du résumé
BACKGROUND
BACKGROUND
Extracellular vesicles (EVs) are a heterogeneous family of small vesicles released by donor cells and absorbed by recipient cells, which represent important mediators with fundamental roles in both physiological and pathological conditions. EVs are present in a large variety of biological fluids and have a great diagnostic and prognostic value. They have gained the interest of the scientific community due to their extreme versatility. In fact, they allow us to hypothesize new therapeutic strategies since, in addition to being cell signal mediators, they play an important role as biomarkers, drug vehicles, and potential new therapeutic agents. They are also involved in immunoregulation, have the ability to transmit resistance to a drug from one cell to a more sensitive one, and can act as drug delivery systems.
OBJECTIVE
OBJECTIVE
The main reciprocal interactions between EVs and immunosuppressive drugs will be presented.
RESULTS
RESULTS
The known interactions between EVs and immunosuppressive drugs, in particular cyclosporin, glucocorticoids, rapamycin, methotrexate, cyclophosphamide, eculizumab, infliximab, certolizumab, etanercept, glatiramer acetate, and fingolimod are presented.
CONCLUSION
CONCLUSIONS
This review provides relevant information on the links between EVs and immunosuppressive drugs with a focus on EVs' role as tools to assess the effects of immunosuppressants, suggesting innovative properties and new possible therapeutic uses.
Identifiants
pubmed: 34879795
pii: CMC-EPUB-119289
doi: 10.2174/0929867328666211208114022
doi:
Substances chimiques
Biomarkers
0
Immunosuppressive Agents
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3586-3600Subventions
Organisme : Institute for Maternal and Child Health “Burlo Garofolo,” Trieste, Italy
ID : RC 1/17, RC 10/19
Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.